文献速递系统性红斑狼疮其他结缔组织病

妊娠早期羟氯喹暴露与重大先天畸形的系统评价与荟萃分析

First trimester exposure to hydroxychloroquine during pregnancy and major congenital malformations: a systematic review and meta-analysis.
PubMed 文献 · RMD Open · 2026-10-26

鉴于HCQ在系统性红斑狼疮中的明确获益,结果不支持改变当前临床实践;其他适应症需个体化评估。

要点

  • HCQ暴露与重大先天畸形风险轻度升高相关(OR=1.27,95%CI 1.11-1.45),证据确定性低。
  • 在校正后分析中关联仍显著(aOR 1.29,95%CI 1.09-1.53)。
  • SLE患者孕期使用HCQ的获益明确,不支持下调整临床实践。

核心结论

  • HCQ暴露与重大先天畸形存在轻微关联,但证据确定性低。
  • 鉴于HCQ在SLE中的明确母胎获益,结果不支持改变当前临床实践。
  • 对于有其他替代药物的适应症,孕期使用应个体化评估。

研究设计与样本

  • 系统评价与荟萃分析,检索MEDLINE、EMBASE、CENTRAL等数据库至2025年7月9日。
  • 纳入RCT和比较性观察研究,共20项(18项队列、1项病例对照、1项RCT)。

主要发现

  • HCQ与任何重大先天畸形的关联OR=1.27(95%CI 1.11-1.45),I²=0.0%,基于19项研究。
  • 基于校正OR的合并关联aOR=1.29(95%CI 1.09-1.53),I²=0.0%,基于8项研究。
  • 偏倚风险:4项严重,15项极严重,1项RCT存在一些问题。

关键数值与推荐

  • 主要结局为任何重大先天畸形。
  • 采用固定效应和随机效应模型基于校正或粗OR进行荟萃分析。
  • 证据确定性低。

临床怎么用

  • SLE患者孕期不应因该结果改变HCQ使用。
  • 其他适应症需权衡利弊,个体化决策。

局限性

  • 纳入研究偏倚风险高(多数为极严重)。
  • 证据确定性低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the association between hydroxychloroquine (HCQ) use during the first trimester of pregnancy and the risk of major congenital malformations (MCMs). METHODS: In this systematic review and meta-analysis, we searched MEDLINE, EMBASE, CENTRAL, clinical trials registers and specialised databases from inception to 9 July 2025. We included randomised controlled trials (RCTs) and comparative observational studies. Study selection and data extraction were performed independently by two reviewers. Risk of bias was assessed using Risk of Bias in Non-Randomised Studies of Interventions or Risk of Bias 2. Primary outcome was any MCM. Meta-analyses used fixed-effects and random-effects models (REM) based on adjusted or crude ORs. RESULTS: From 4311 records, we included 20 studies (18 cohorts, 1 case-control and 1 RCT) including 4260 HCQ-exposed and 361 802 unexposed-pregnancies. The risk of bias was serious (n=4), critical (n=15) and ‘some concern’ (n=1, RCT). A significant association was found between HCQ and any MCM (OR=1.27, 95% CI (1.11 to 1.45) for REM, I2=0.0%, Tau2=0, n=19 studies). The pooled association based on adjusted OR was also statistically significant (aOR 1.29, 95% CI (1.09 to 1.53) for REM, I²=0.0%, Tau2=0, n=8). The certainty of evidence was low. CONCLUSION: A slight association between HCQ exposure and MCM was observed, with low certainty of evidence. Given the well-established maternal/fetal benefits of HCQ in systemic lupus erythematosus, these results do not support changes in current clinical practice regarding its use during pregnancy. For other indications where alternatives exist, its use during pregnancy should be considered on a case-by-case basis. PROSPERO REGISTRATION NUMBER: CRD420250609725.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Cournand E, Teboul A, Costedoat-Chalumeau N, et al. First trimester exposure to hydroxychloroquine during pregnancy and major congenital malformations: a systematic review and meta-analysis. RMD Open. 2026. PMID: 42933791. doi:10.1136/rmdopen-2026-007015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。